

Special Issue

Antimicrobial Silver in Medicinal Applications

Message from the Guest Editor

The last decade has witnessed an increased interest in the development and usage of silver as an antimicrobial agent in numerous fields. There are reports describing silver ions and nanoparticles highly potent against multi-drug resistant bacteria with comparatively minimal toxicity to mammalian cells. However, bacterial resistance against silver was also documented with controversies present in literature regarding safety of the increased quantity of commercially available products incorporating silver nanoparticles. This Special Issue is dedicated to topics concerning:

- availability of antimicrobial silver products in wide medicinal applications as alternative treatments;
- caution of proper choice of controls and monitoring of medical safety of silver products;
- environmental contamination and recycle of silver antimicrobial agents;
- investigations into mode of action with proposed mechanisms of antibiotic-resistance and the potential synergistic effects of silver complexed with antibiotics or other natural antimicrobials.

Manuscripts including research related to the themes mentioned above are welcome.

Guest Editor

Dr. Zyta M. Ziora

Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia

Deadline for manuscript submissions

closed (15 July 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/71013

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)